Amendment: Regulations Amending the Patented Medicines (Notice of Compliance) Regulations, SOR/2015-0169
Date in force: June 19, 2015
Date of publication (Canada Gazette, Part II, Vol. 149, No. 13): July 1, 2015
The amendments to the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations), as brought into force on June 19, 2015 (the Amendments), have now been officially published with an accompanying Regulatory Impact Analysis Statement in Canada Gazette, Part II, Vol. 149, No. 13.
Key Features of the Amendments
The Amendments confirm the Minister of Health's (Minister) longstanding policy and practice of listing patents claiming a single medicinal ingredient on the Patent Register with respect to combination drug products. The Amendments were precipitated by two recent Federal Court cases (Gilead and ViiV) holding that listing patents claiming single medicinal ingredients on the Patent Register against combination drug products was inconsistent with paragraph 4(2)(a) of the PM(NOC) Regulations.1
We previously reported on the key features of the Amendments prior to today's official publication [ Pharma in brief of June 25]. The key features of the Amendments are the following:
1. 30 day deadline to obtain recourse for patents deleted or denied listing
The Amendments provide redress for innovators whose patents were deleted from, or refused listing on, the Patent Register from October 18, 2014 to June 19, 2015 on the basis of the ViiV decision. Eligible patent lists may be resubmitted to the Minister in relation to the submission or supplement for addition to the Patent Register within 30 days after June 19, 2015.
2. New interpretational rules impacting combination drugs
New subsection 4(2.1) introduces rules that apply when determining the eligibility of a patent to be added to the register under paragraphs 4(2)(a) ('claim for the medicinal ingredient') and 4(2)(d) ('claim for the use'). In particular:
- a patent that contains a claim for the medicinal ingredient is eligible for listing even if the submission includes, in addition to the medicinal ingredient claimed in the patent, other medicinal ingredients; and
- a patent that contains a claim for the use of the medicinal ingredient is eligible for listing if the submission includes the use claimed in the patent, even if: (i) the submission includes additional medicinal ingredients, (ii) the submission includes other additional uses of the medicinal ingredient, or (iii) the use that is included in the submission requires the use of the medicinal ingredient in combination with another drug.
3. New provisions impacting formulation claims
A new definition of "claim for the formulation" has been introduced. The Amendments state that a "claim for the formulation" need not specify the non-medicinal ingredients contained in the submission in order to be eligible for listing on the Patent Register. If the claim does specify non-medicinal ingredients, however, those non-medicinal ingredients must be contained in the submission.
4. Transitional provision
The court shall apply the PM(NOC) Regulations, as amended, in any ongoing subsection 6(1) application or paragraph 6(5)(a) motion initiated between the prepublication date of the Amendments (May 2, 2015) and the date upon which the Amendments came into force (June 19, 2015).
Jurisprudential background: Gilead and ViiV
Since 2006, paragraph 4(2)(a) of the PM(NOC) Regulations has permitted a claim for the approved medicinal ingredient of a drug to support listing a patent on the Patent Register in respect of that drug. The Minister's established policy and practice applied paragraph 4(2)(a) to support the patent list eligibility of a patent claiming a single medicinal ingredient with respect to a combination drug. The decision in ViiV-FC, relying upon earlier findings of the Federal Court of Appeal in Gilead, disturbed this established interpretation by finding paragraph 4(2)(a) to require that a patent claim all medicinal ingredients contained in the approved combination drug in order to be eligible for listing on the Patent Register with respect to that drug.
- Canada Gazette, Part II, Vol. 149, No. 13, pp. 2203-2211 Regulations Amending the Patented Medicines (Notice of Compliance) Regulations
- Gilead Sciences Canada Inc v Canada (Minister of Health), 2012 FCA 254 [Gilead], var'g 2012 FC 2 concerning the FDC, COMPLERA®; ViiV Healthcare ULC v Teva Canada Limited, 2015 FCA 93 [ViiV-FCA], aff'g 2014 FC 893 [ViiV-FC], aff'g 2014 FC 328 [collectively, ViiV], concerning the FDC, KIVEXA®.
Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.